GLP-1 Market
LLY $1347.11 ▼ -0.3% NVO $37.82 ▼ -2.7% PFE $27.40 ▼ -0.5% VKTX $24.77 ▼ -4.1% KLRA $11.02 ▼ -4.8% GPCR $16.13 ▼ -5.8% RHHBY $58.46 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Recaticimab

Company
Xiangya Hospital of Central South University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for Recaticimab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06467617

    Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

    Not yet reported Beijing Chest Hospital, Capital Medical University 35 participants Est. completion 2027-03-01 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06738758

    Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)

    Yun Dai Chen 6000 participants Est. completion 2027-12-31 1 site
    Other conditions: Acute Coronary Syndromes
    View official trial listing →
  • Recruiting NCT NCT06902740

    PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

    Not yet reported Peking Union Medical College Hospital 300 participants Est. completion 2028-12-31 19 sites Stand-alone
    Other conditions: Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
    View official trial listing →
  • Recruiting NCT NCT07002476

    Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion

    Not yet reported Shanghai East Hospital 978 participants Est. completion 2027-06-01 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07062328

    A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

    Not yet reported Sun Yat-sen University 39 participants Est. completion 2028-04-20 Stand-alone
    Other conditions: Biliary Tract Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT07119918

    PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 5276 participants Est. completion 2029-12-01 1 site Stand-alone
    Other conditions: Symptomatic Intracranial Atherosclerotic Stenosis
    View official trial listing →
  • Not yet recruiting NCT NCT07290699

    Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period

    Not yet reported Second Affiliated Hospital of Nanchang University 2442 participants Est. completion 2028-08-30 Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Not yet recruiting NCT NCT07373847

    Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

    Not yet reported Xiangya Hospital of Central South University 40 participants Est. completion 2027-08-30 Stand-alone
    Other conditions: Plaque Psoriasis
    View official trial listing →
  • Not yet recruiting NCT NCT07466251

    PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke

    Not yet reported Peking Union Medical College Hospital 1212 participants Est. completion 2029-12-31 19 sites Stand-alone
    Cardiovascular disease Other conditions: Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
    View official trial listing →
  • Not yet recruiting NCT NCT07567326

    Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC

    Not yet reported Peking University Cancer Hospital & Institute 78 participants Est. completion 2030-12 Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07605130

    Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter Trial

    Not yet reported Peking Union Medical College Hospital 440 participants Est. completion 2029-07-31 1 site Stand-alone
    Other conditions: Intracranial Arteriosclerosis, Cognitive Impairment
    View official trial listing →
  • Not yet recruiting NCT NCT07674368

    Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

    Not yet reported Hunan Cancer Hospital 29 participants Est. completion 2028-08-01 1 site Stand-alone
    Other conditions: ALK Fusion-positive Non-small Cell Lung Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07951320

    Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors

    Not yet reported Xiangya Hospital of Central South University 100 participants Est. completion 2028-09-30 7 sites Stand-alone
    Other conditions: Plaque Psoriasis, Dyslipidemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.